Bio AI startup Amplii announced on the 30th that it has secured seed investment from deep tech accelerator Bluepoint Partners.


Bluepoint Invests Seed Capital in Bio AI Startup 'Amplii' View original image

Amplii aims to build a “biochemical daily diagnostic platform” that overcomes the structural limitations of conventional daily diagnostic solutions, namely low sensitivity, high cost, and inconvenient usability.


Based on the “Triple S” diagnostic technology developed from Yonsei University’s nano-bio research, Amplii applied the world’s first clip-type compression sampling method to address the challenge of detecting low-concentration substances. In addition, Amplii’s ultra-sensitive bio-AI diagnostic system “A Cube” and deep learning-based quantitative analysis technology “Amp Vision” enable a reading accuracy of up to 99%.


Since its establishment in July 2024, Amplii has developed and launched multiple products, generating actual sales. Through its own consumer brand “Winti,” the company has released a range of products that enable comprehensive self-diagnosis in daily life, including the LIV8 nutrition balance self-diagnosis kit, the SkinCheck smart skin pH diagnostic kit, the MSK male fertility diagnostic kit, and the ASK post-coital self-diagnosis kit. The diagnostic results lead to purchases of personalized solutions, establishing a data-driven repeat consumption mechanism that conventional consumer goods companies find difficult to secure.


Leveraging this technological prowess, Amplii jointly developed a smart diaper-based baby health diagnostic solution with Yuhan-Kimberly. The solution quantitatively analyzes biometric indicators at the moment urine is absorbed into the diaper, allowing for the assessment of nutritional status and abnormal signals. As a result of this collaboration, the two companies received an award from the Minister of SMEs and Startups.


Moon Subin, Investment Manager at Bluepoint Partners, commented, “We are impressed by the team’s execution in repeatedly developing and launching products in a short period based on their own technology and generating real sales. The structure in which diagnostic results drive consumer behavior is a differentiated competitive factor that traditional consumer goods companies find difficult to secure, and we expect Amplii to establish a meaningful position in the wellness consumer goods market.”



Kim Junmin, CEO of Amplii, stated, “We aim to create a future where people can easily and accurately check and manage their health as part of everyday life.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing